Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber
Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients
Dr. Jeffery Weber will present data from a collaboration in which proteomic tests developed by Biodesix® could help guide therapy choices in immuno-oncology. These blood-based tests, which were developed on Biodesix’s proprietary Diagnostic Cortex™ platform, may identify patients who derive significant benefit from anti-PD-1 monotherapy and might not gain additional benefit from the addition of anti-CTLA-4 agents. Dr. Weber will make his presentation at the 4th Immunotherapy of Cancer Conference in Europe (ITOC4).
Session Title: Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients
Plenary Session Date/Time: Tuesday March 21, 4:50PM
Location: Prague Congress Center, 5 Kvetna 65, Prague, Czech Republic
About Jeffery Weber
Jeffrey S. Weber, MD, Ph.D, is the deputy director of the Perlmutter Cancer Center at New York University – Langone Medical Center, where he serves as a Professor in the Department of Medicine. Dr. Weber is co-director of the Center’s Melanoma Research Program.
Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix designs, develops and commercializes multivariate molecular liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with real-time clinical data at diagnosis with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel clinical tests independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.